Intermuscular Coherence as a Biomarker for ALS

Exclusion Criteria

• •AIM 1:
• •1. Classified as probable or definite ALS by Awaji criteria prior to initial study evaluation
• •2. Have significant sensory loss in the weak or spastic limbs
• •3. Have significant musculoskeletal or neuropathic pain
• •4. Have an inability or are unwilling to provide informed consent
• •5. Are unable to perform the study-related task
• •6. Are taking baclofen or benzodiazepines
• •7. Have a known non-ALS cause for symptoms
• •AIM 2:
• •1. Have a history of neurological disorders such as stroke, neuropathy, or myopathy
• •2. Have significant pain or sensory loss
• •3. Are taking baclofen or sedatives such as benzodiazepines
• •4. Lack of cognitive ability or willingness to provide informed consent
• •AIM 3:
• •1. Were unclassified according to the Awaji category or had a defined ALS mimic
• •2. Are taking baclofen, sedatives or benzodiazepines.
• •NOTE: Participation in a therapeutic clinical trial is NOT an exclusion criterion since this study would not interfere with any potential interventions.